{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"89.8","upperLimit":"99.6","value":"97.1"},{"groupId":"OG001","lowerLimit":"66.4","upperLimit":"100.0","value":"100.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants who achieved partial response (PR) or better according to international myeloma working group (IMWG) criteria. IMWG criteria for PR: greater than or equal to (\\>=) 50 percent (%) reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\>=90% or to less than (\\<) 200 milligrams (mg) per 24 hours. If the serum and urine M-protein were not measurable, a decrease of \\>=50% in the difference between involved and uninvolved free light chain (FLC) levels was required in place of the M-protein criteria. If serum and urine M-protein were not measurable, and serum free light assay was also not measurable, \\>=50% reduction in bone marrow plasma cells (PCs) was required in place of M-protein, provided baseline bone marrow PC percentage was \\>=30%. In addition to the above criteria, if present at baseline, a \\>=50% reduction in the size of soft tissue plasmacytomas was also required.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received a conditioning regimen of cyclophosphamide 300 mg/m\\^2 IV infusion and fludarabine 30 mg/m\\^2 IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received recommended phase 2 dose (RP2D) dose of JNJ-68284528 0.75\\*10\\^6 CAR positive viable T cells/kg as IV infusion.","id":"OG000","title":"Phase 2 (US Population)"},{"description":"Participants received a conditioning regimen of cyclophosphamide 300 mg/m\\^2 IV infusion and fludarabine 30 mg/m\\^2 IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received RP2D dose of JNJ-68284528 0.75\\*10\\^6 CAR positive viable T cells/kg as IV infusion.","id":"OG001","title":"Phase 2 (Japan Population)"}],"paramType":"NUMBER","populationDescription":"Modified intent-to-treat (mITT) analysis set included all participants who received a JNJ-68284528 infusion at the targeted recommended phase 2 dose (RP2D) dose level. Here, N (number of participants analyzed) signifies participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Day 1 up to 45.2 months","title":"Phase 2: Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}